Arena Pharmaceuticals Announces The Presentation Of Lorcaserin Phase 3 BLOOM Data At The American Diabetes Association’s 69th Scientific Sessions
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced that a late-breaking abstract of its lorcaserin Phase 3 BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) trial has been accepted for a poster presentation at the American Diabetes Association’s 69th Scientific Sessions in New Orleans, Louisiana.
More: continued here
Filed under: Clinical Trials on June 4th, 2009
You must be logged in to post a comment.